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The manuscript shows that HPV-16 E5 down-regulates and physically interacts with HLA 
class I via the first 30 N-terminus amino acid residues. This N-terminus domain is capable by 
itself of retaining HLA class I in the Golgi apparatus and preventing the anterograde transport 
of the complex to the cell surface.   
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Abstract 
Human papillomavirus type 16 E5 protein (HPV-16 E5) is expressed early in papillomavirus 
infection and is localised primarily in the cell Golgi apparatus and endoplasmic reticulum. E5 
prevents transport of the major histocompatibility class I (MHC I; HLA class I in humans) to 
the cell surface and retains the complex in the Golgi apparatus. We report that these effects 
are due, at least in part, to the interaction between E5 and HLA I heavy chain. We also 
demonstrate that the down-regulation of surface HLA I, and interaction with HC are mediated 
by the first hydrophobic domain of E5. Although E5 down-regulates classical HLA 
selectively as it does not down-regulate non-classical HLA, the interaction with the HC of 
classical HLA I is not specific for a particular haplotype of HLA I. This suggests that E5 can 
interfere with antigen presentation by most, if not all, classical HLA I haplotypes, with 
potentially serious consequences as the ability of infected cells to present antigenic peptides 





Human papillomaviruses (HPVs) infect mucosal and cutaneous epithelia, and induce lesions 
that can persist and progress to cancer. The mildest forms of HPV disease are benign 
hyperproliferative lesions, known as warts or papillomas. In most cases these lesions are 
cleared after several months following activation of the host immune system against viral 
antigen 1. However, due to the ability of certain types of HPVs to avoid immune clearance, 
occasionally the lesions do not regress and can progress to cancer. This is especially true for 
HPV type 16 which is involved in the majority of cases of HPV-induced cervical cancers 2. 
The ability of the virus to avoid immune clearance is due to several factors dependent on the 
virus life cycle, but also on active mechanisms operated by the viral proteins to counteract the 
host immune attack. Elimination of virally infected cells requires cytotoxic T-lymphocytes 
(CTL) that can recognise and kill virally infected cells via ligation of their receptor to major 
histocompatibility class I complex (MHC I; HLA I in humans) bound to viral peptides on the 
surface of infected cells 3.  
One of the potential effectors of HPV-16 escape from host immunosurveillance is the viral 
oncoprotein E5 4. E5 is a hydrophobic membrane protein 83 amino acids long, possessing 
three well-defined hydrophobic regions. E5 is expressed early in papillomavirus infection in 
the deep layers of the infected epithelium 5, 6 (Araibi et al., unpublished results) and is 
localised mainly in the endoplasmic reticulum (ER) and Golgi apparatus (GA) membranes 7. 
We have previously shown that HPV-16 E5 down-regulates the expression of surface HLA I 
by retaining the complex in the GA, and this down-regulation is selective, as E5 does not 
interfere with non-classical MHC. This may allow the virus to establish itself by avoiding 
clearance of virus-infected cells by both CTL and natural killer cells (NK) 4. 
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Here we show that E5 physically interacts with the heavy chain (HC) of HLA I and that 
interaction and down-regulation of surface HLA I are mediated by the first hydrophobic 
domain of E5.  
 
 
Materials and methods 
Construction of HPV-16 E5 mutants 
The plasmid pcDNA-Neo (Invitrogen, UK), encoding G418 resistance and containing the 
universal IE promoter of CMV, was used to express HPV-16 E5 wild type (wt) or mutant 
forms, all tagged with the hemagglutinin (HA) epitope YPYDVPDYA at their N-terminus. 
HPV-16 E5 deletion mutants R79, A54, V36 and R30 (gift of Dr Alonso, Deutsches 
Krebsforschungszentrum, Heidelberg, Germany) were generated by introducing double stop 
codons at the respective nucleotide positions of the HPV 16 E5 sequence 8. HPV-16 E5 Del1 
mutant protein was made by deletion of the first hydrophobic domain (amino acids 1-30) by 
PCR amplification using forward primer from nt 91 to 105 of the HPV-16 E5 ORF 
(5’cattgctagcatgtacccatacgatgttccagattacgctccgctgcttttgtct3’) and reverse primer from nt 252 
to 231 (5’tcgcgaattcttatgtaattaaaaagcgtg3’) including sites for Eco RI and Nhe I respectively. 
The resulting PCR products were inserted between the Eco RI and Nhe I sites of pcDNA-Neo. 
All clones were verified by sequencing. 
 
Construction of GFP-E5 fusion proteins  
pEGFP-C1 (Clontech, UK) is a eukaryotic expression plasmid which encodes the green 
fluorescent protein (GFP). It was used to clone full length HPV-16 E5 and its mutants to 
generate GFP-E5 wt and GFP-E5 mutant fusion proteins by PCR. The forward primer was 
from nt 1 to 22 of the E5 ORF for E5 wt and mutants R79, A54, V36 and R30, and from nt 
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91 to 112 for the Del1 mutant. The reverse primers were from nt 252 to 231 for Del1, from 
237 to 216 for R79, from 162 to 141 for A54, from 111 to 90 for V36, and from 93 to 72 for 
R30. The forward and reverse primers included an Eco RI and a Bgl II site respectively. The 
resulting PCR products were inserted between the Eco RI and Bgl II sites of pEGFP-C1. All 
clones were verified by sequencing. 
 
Cell culture and transfection  
The immortalised human keratinocyte (HaCaT) cell line was grown in Dulbecco's modified 
Eagle medium high glucose without calcium chloride (Life Technologies, UK), supplemented 
with 10% foetal calf serum, as previously described 9. One x 106 cells were stably transfected 
with 4μg pcDNA, pc-16E5 or pc-16E5 mutants by using Lipofectamine Plus (Invitrogen). 
Following transfection, HaCaT cells were selected in medium containing 500μg/ml G418 for 
21 days. G418-resistant colonies were marked, picked and expanded into cell lines for 
analysis.  
 
Real time/quantitative RT-PCR 
RNA was isolated from HaCaT cells using the RNAeasy Mini kit (Qiagen, Sussex, UK), and 
residual DNA was removed by DNAase I treatment according to the manufacturer’s 
guidelines (Invitrogen, UK). Real-time RT-PCR for E5, E5 mutants and β-actin mRNA was 
carried out using the Taqman EZ RT-PCR kit (Applied Biosystems, Foster City, CA, USA) 
with gene-specific primers and FAM/TAMRA probe designed by primer express v1.7 
software. 100ng RNA was used per each reaction, done in triplicate. Primers were as follows: 
forward (F) primer for E5 wt, R79, A54, V36 and R30 was 5’tgacaaatcttgatactgcatcca3’; 
reverse (R) primer for E5, R79 and A54 was 5’tgacaaatcttgatactgcatcca3’; R primer for V36 
and R30 was 5’taataggcagacacacaaa3’.  
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The probe was 5’aacattactggcgtgctttttgctttgct3’ in all cases. For ß-actin, primers and probe 
were commercially available (Applied Biosystems). Standard curves were generated using 
10-fold serial dilutions of each template DNA, to quantify the relative levels of E5 and β-
actin mRNA.  
 
Semi-quantitative RT-PCR 
Real time RT-PCR did not work for E5 Del1 as no appropriate forward primer could be 
identified outside the first hydrophobic domain that matched the probe. Therefore, to quantify 
the levels of E5 Del1, semi-quantitative RT-PCR was performed9. The Del1 F primer was 
5’ctgcttttgtctgtgtctacata3’ and the R primer was 5’tataatatatacaataaaacacctaa3’. RT-PCR was 
performed using an ABI prism 7700 sequence detector for 20, 25, 30 or 35 cycles. The same 
amplification protocol was used with E5 wt and R30 as controls. The RT-PCR products were 




Fifty µg of protein lysates from HaCaT cell harbouring empty vector (Control), expressing 
Del1 or E5, were electrophoresed, and transferred to nitrocellulose membrane. The 
membranes were blocked and incubated with mAb HA11 (1/500 dilution; Sigma) for 1 hour, 
washed and incubated with anti-mouse IgM-HRP (1/5000; Oncogene Calbiochem-
Novabiochem International). After 1 hour the membranes were washed and bound antibody 





Detection of HLA I by flow cytometry was performed essentially as previously described 4. 
Briefly HaCaT cells and cells expressing E5 and mutants were incubated with anti-human 
HLA class I monoclonal antibody (mAb) W6/32 (1/100; Serotec), at 4°C for 30 min, and then 
with anti-mouse IgG-FITC (1/100; Sigma) at 4°C for 30 min in the dark.. After washing the 
cells were analysed by flow cytometry. If the flow cytometry analysis was not performed 
immediately, the cells were re-suspended in 500μl of 3.4% paraformaldehyde in PBS and 
kept at 4°C. For the detection of intracellular HLA I, the cells were permeabilised with 0.5% 
Saponin (Sigma) in PBS-B and incubated with the primary antibody as described above. All 
samples were examined in a Beckman Coulter EPICS Elite analyser equipped with an ion 




Detection of HLA I by immunofluorescence was performed essentially as previously 
described 4. Briefly, cells were washed and fixed in fixing solution (19ml PBS, 1ml 37% 
formaldehyde and 0.4g sucrose) for 10 minutes at room temperature (RT). After fixation, 
cells were incubated in permeabilising solution (19ml PBS, 1ml 10% NP40 and 0.4g sucrose) 
at RT for 10 minutes, incubated with mAb W6/32 (1:50 dilution) for 1 hour at room 
temperature and then with anti-mouse IgG-FITC (1/500;Sigma) at 4°C for 1 h in the dark. 
Following three final washes with PBS, the slides were mounted in CitifluorTM (glycerol/PBS 
solution, Sigma) and analysed with a Leica TCS SP2 fluorescence confocal microscope 




Co-localisation of Golgi apparatus and E5 
HaCaT cells were transiently transfected with 0.1 μg of either pEGFP-E5 or pEGFP-E5 
mutants, or with control empty plasmid, using Lipofectamine Plus™ Reagent according to 
the manufacturer's instructions. Seventy-two hours after transfection, cells were plated 
approximately 25-50% confluent, and grown overnight. Cells were washed twice with serum 
free DMEM, 25mM Hepes (DMEM-H) and incubated in 200μl of 5μM BODIPY-TR-
ceramide, which localises to the GA, in DMEM-H for 30 min at 4oC. Cells were washed 
twice with PBS and fixed in fixing solution as above, and washed three times with PBS. Cells 
were incubated with 4′6′-diamino-2-phenylindole (DAPI) for 10 min, to stain the nucleus, 
washed in PBS–FCS and then distilled water, dried and mounted in CitifluorTM (Sigma). 
Cells were analysed with a Leica TCS SP2 confocal scanner microscope. Images were 
acquired and merged using Leica confocal software. 
 
Co-immunoprecipitation of E5 and HLA heavy chain in HaCaT cells 
Control or E5-HaCaT cells were lysed in RIPA buffer (50mM Tris HCl pH 7.5, 150mM 
NaCl, 1% Nonidet P40, 0.5% NaDoc, 0.1% SDS) containing a cocktail of protease inhibitors 
(Roche, Lewes, UK). 100 μg of protein lysate were immunoprecitated with 50 µl of mAb 
HA11 (1:10 diluition; Sigma) against the HA-tag of E5 and then incubated at 4°C overnight. 
After that, protein G-sepharose bead suspension (Sigma) was added for 1 h at 4oC. 
Following four washes in RIPA buffer the sepharose beads were resuspended in 20 μl of SDS 
loading buffer, heated at 75oC for 10 min, and then electrophoresed in 12% NuPAGE gels 
(Invitrogen). Proteins were transferred onto nitrocellulose membranes and immunoblotted 




In vitro transcription/translation and co-immunoprecipitation 
HLA heavy chain A2 cDNA sequence in pAL356 was excised and re-cloned in pBluescript II 
SK (+) (Stratagene); HLA heavy chain A1 or B8 cDNA sequences in pRSV5-neo were 
excised and re-cloned in pGEM-11Zf (Promega, UK). All HLA heavy chain plasmids were a 
gift from Dr S. Man, University of Cardiff, UK.  HPV-16 E5 or E5 mutants, and A1, A2 or 
B8 were in vitro transcribed–translated using the TNT® T7 Quick Coupled 
Transcription/Translation System (Promega, UK) in presence of Redivue L-[35S] Methionine 
(Amersham Pharmacia Biotech, UK) following the manufacturer instructions, and as 
described previously 10. Half of each transcription/translation reaction product was 
immunoprecipitated with 3 µl of mAb HA11 (1:10 diluition; Sigma) or, in the case of R30, 3 
µl of a polyclonal antiserum raised against the N-terminus of E5 (gift of Prof D. DiMaio, 
Yale University, USA; Hwang et al., 1995), or 10 µl mAb HC10 against HLA-A, B, C (1:250 
dilution; Cancer Research, UK) and then incubated at 4°C overnight. The other half of each 
reaction was left without antibody as a negative control. For co-immunoprecipitation the 
individual transcription/translation products (25 µl each of HLA heavy chain and E5 
reactions) were mixed in equivalent amounts and immunoprecipitated with double the 
amount of either antibody. For competition experiments, unlabelled R30 or Del1 was added 
to labelled HLA-A2 overnight before the addition of labelled E5 and antibody as above. After 
incubation overnight at 4oC, protein G-sepharose bead suspension (Sigma) was added for 1 h 
at 4oC. Following two washes in a high salt buffer (50mM Tris HCl pH 7.5, 500mM NaCl, 
1% Nonidet P40, 0.05% NaDoc) and one wash in a low salt buffer (50mM Tris HCl pH 7.5, 
1% NonidetP-400, 0.05% NaDoc) the beads were resuspended in 20 μl of SDS loading 
buffer, heated at 75oC for 10 min, and electrophoresed in 4-12% NuPAGE gels (Invitrogen). 
Gels were fixed with glacial acetic acid and methanol, incubated for 15 min in AmplifyTM 
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Fluorographic reagent (Amersham, UK), dried and exposed for autoradiography at –70oC 




HPV-16 E5 and HLA I heavy chain interact physically 
HPV-16 E5 prevents the transport of HLA class I to the cell surface by retaining the complex 
in the GA 4. We have recently shown that BPV-4 E5 physically interacts with the HC of the 
bovine MHC I, providing an additional mechanism to the alkalinisation of the GA for the 
retention of the complex in the GA 10, 11. To investigate whether this was the case also for 
HPV-16 E5, we performed co-immunoprecipitation experiments between E5 and HLA I HC 
with monoclonal antibody (mAb) HA11 (against the HA tag of E5), in E5-expressing and 
control HaCaT keratinocytes, which are known to express HLA-A3, A31 B60 B51. A clear 
band was present in the precipitate from E5-expressing cells, while no band corresponding to 
HC was detected in the precipitate from control cells (Figure 1A, lanes 4 and 7). In addition 
to being detected by mAb HC10, specific for HLA class I, the band corresponded to the HC 
detected in the protein lysate by western blotting (Figure 1A, lanes 1 and 2), leading to its 
identification as HC, and to the conclusion that E5 and HLA-A3 HC (and possibly A31 B60 
B51, as suggested by the double HC band) exist in a physical complex in E5-expressing 
HaCaT cells. (Del1 is a non-interacting mutant of E5 which is described later). The relative 
faintness of the HC band co-precipitated with E5 is due to the very low levels of E5 in these 
cells: E5 is expressed at approximately four orders of magnitude lower than actin (see Figure 
2B and 4. Additionally we performed an in vitro co-immunoprecipitation experiment between 
35S-labelled E5 and HLA-A2 HC, as a similar experiment had already validated the 
interaction between BPV-4 E5 and bovine MHC I heavy chain 10. Physical interaction 
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between E5 and HC was confirmed by the co-immunoprecipitation of 35S-labelled E5 and 
HLA-A2 with mAb HC-10 (Figure 1B, lane 7). Moreover, the formation of a complex 
between E5 and HLA-A2 HC in vitro indicates that the interaction is not specific for a 
particular HLA I haplotype.      
 
E5 interacts with the HC of different HLA I haplotypes  
To investigate whether E5 interacts with different HC, and as the in vitro interaction between 
E5 and HC reflects the interaction occurring in vivo, we performed in vitro co-precipitation 
experiments with E5 and A1 or B8 HC. In both cases, E5 and HC co-precipitated when either 
mAb HC10 or mAb HA11 was used (Figure 1D-G, lanes 7). Although a faint band 
corresponding to A1 or B8 HC was detected with mAb HA11 even in the absence of E5, the 
band was stronger when E5 was present, particularly in the case of B8, giving confidence that 
the co-precipitation reflects a genuine interaction.  As E5 interacts with A3 in HaCaT cells, 
and with A1, A2 and B8 in vitro, we conclude that the interaction between E5 and HC is 
likely to take part with most, if not all, classic HLA I alleles.  
 
Characterisation of E5 mutants 
HPV-16 E5 is a transmembrane protein containing three well defined hydrophobic regions, of 
which the first one is the longest 12, 13. To determine the E5 domain responsible for down-
regulation of surface HLA I, deletion mutants of E5, lacking helical domain 1, 2 or 3, were 
assayed for their ability to retain HLA I in the GA. Mutant R79 lacks the last five C-terminal 
amino acids, A54 lacks the complete third hydrophobic domain, V36 and R30 lack the 
second and third hydrophobic domains, and Del1 lacks the first hydrophobic domain (Figure 
2A). Before any analysis of the E5 mutants was carried out, we made sure that their 
expression and cellular localisation were not different from those of E5 wt.   
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Expression of E5 in stably transfected cells. We verified that the E5 proteins were being 
transcribed to a similar extent using quantitative RT-PCR (Q-RT-PCR). RNA was isolated 
from three clones each of HaCaT keratinocytes stably transfected with E5 wt or mutants. The 
level of E5 or E5 mutant RNA (with the exception of E5 Del1, see below) was determined 
and compared to the level of ß-actin RNA. Representative results from one clone each of E5 
wt and mutants are shown in Figure 2B. The levels of E5 wt or mutant RNA were very low, 
approximately four orders of magnitude less than actin RNA as previously found 4; however, 
they were comparable among clones, ranging approximately from 0.02 to 0.03 pg per 100ng 
RNA.  
Del1 RNA could not be amplified by Q-RT-PCR because no forward primer compatible with 
the probe could be identified outside the first hydrophobic domain, so semi-quantitative RT-
PCR was used instead. Also in this case, there was no appreciable difference in the amounts 
of RNA between E5 wt and mutants, including Del1 (Figure 2C).  
 
Cellular localisation of E5 proteins. Given the very low expression levels of E5, it is not 
possible to determine the cellular location of the protein by cytoimmunofluorescence. 
Therefore we decided to analyse E5 location by the use of GFP-E5 fusion proteins. The 
correct cellular localisation of GFP-E5 fusion proteins has been reported 14. HaCaT cells were 
transiently transfected with plasmids encoding GFP-fusions of E5 or E5 mutants or empty 
EGFP vector; the GA was visualised by using the Golgi marker BODIPY-TR-ceramide and 
the nucleus was stained with DAPI. The localisation of the GFP-fusion proteins was 
determined by three-colour confocal microscopy. There was no discernible difference in 
localisation between E5 and its mutants; in all cases, the E5 proteins were localised in the 
endomembranes, mainly the GA, as shown by the merged images (Figure 2D). 
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The first hydrophobic domain of E5 is responsible for surface HLA I down-regulation 
As E5 wt and mutants were expressed to comparable levels and localised to similar cellular 
compartments, we next investigated which E5 domain(s) was responsible for prevention of 
transport of MHC class I to the cell surface and retention of the complex in the GA. Using 
flow cytometry we determined the levels of both surface and total (surface plus intracellular) 
HLA I in parental HaCaT, control cells harbouring empty vector, cells stably expressing E5 
wt or mutants. Control cells were no different from parental cells, with approximately half as 
much surface HLA I than total HLA I (Figure 3A). In clones expressing E5 wt the levels of 
surface HLA I were reduced to approximately half that of control cells, as previously 
reported 4; likewise, clones expressing the E5 mutants containing the first hydrophobic 
domain (R79, A54, V36, R30) had reduced levels of surface HLA I to the same extent as E5 
wt (Figure 3A). In contrast, expression of E5 Del1, lacking the first hydrophobic domain, did 
not have any effect on the levels of surface HLA I (Figure 3A). The failure of E5 Del1 to 
down-regulate surface HLA I could be due to impaired stability of the protein. However, 
western blotting of protein lysates from E5 wt- or E5 Del1-expressing HaCaT cells showed 
that this is not the case as E5 wt and E5 Del1 were present at comparable levels (Figure 1C, 
lanes 1 and 3).     
From these results, we conclude that the first N-terminus 30 amino acids of E5 are 
responsible for the down-regulation of HLA I. 
 
This conclusion was confirmed by the localisation of HLA I in HaCaT cells expressing the 
E5 proteins. Cells carrying empty vector, expressing E5 wt or E5 mutants were stained with 
mAb W6/32 and analysed for HLA I by cytoimmunofluorescence. In cells expressing E5 wt 
or mutants R79, A54, V36 or R30 (all containing the first hydrophobic domain), HLA class I 
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was detected only intracellularly (Figure 3B); in contrast, in cells expressing E5 Del1 HLA I 
was detected both on the cell surface and intracellularly, as in control cells (Figure 3B). 
These results, together with those obtained by flow cytometry, confirm that E5 amino acids 
1-30 are responsible for the retention of HLA class I complex in the GA. 
 
HPV-16 E5 binds HLA I heavy chain via its first helical domain 
E5 interacts with HLA I HC (Figure 1) and prevents the transport of HLA I to the cell surface 
via its first hydrophobic domain (Figure 3). To investigate whether the same E5 domain was 
responsible for the interaction with HC, we performed in vivo and in vitro co-
immunoprecipitation experiments as above. In HaCaT cells expressing E5 Del1, 
immunoprecipitation with mAb HA11 failed to precipitate HC (Figure 1A, lanes 5 and 6), 
although in immunoblots HC was easily detected by mAb HC10 (Figure 1A, lane 3) and E5 
Del1 and E5 wt were expressed at comparable levels at both mRNA and protein levels 
(Figure 1C, lanes 1 and 3, and 2C). 
In in vitro co-immunoprecipitations, E5 wt and all the mutants containing the first helical 
domain (including R30, which contains only the first N-terminus 30 amino acids) co-
precipitated with HLA-A2 HC (Figure 4A, lane 7, and B, lane 2, shown only for A54 and 
R30). Despite the presence of non-specific bands also in the lanes without antibody (some 
deriving from the translation of E5 and its mutants, possibly representing multimers of E5; 
see input lanes), mAb HC-10 co-precipitated in each case both A2 and the E5 proteins 
(marked with a black dot in Figure 4). In contrast, Del1 failed to co-precipitate with HLA-A2 
HC (Figure 4B, lane 5). Co-immunoprecipitation between R30 and HLA-A2 HC was 
confirmed by using an antibody raised against the N-terminus of E5 15. Also in this case, 
HLA-A2 HC co-precipitated with R30 (Figure 4C, lane 2), validating the results obtained 
with mAb HA11 and HC10. These data indicate that the interaction between E5 and HC takes 
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place via the N-terminus first 30 amino acids. This was confirmed by competition 
experiments. The addition of unlabelled R30 (containing the first 30 amino acids) to the 
reaction prevented the interaction between E5 and A2 HC (Figure 4D, lane 5), whereas the 
addition of unlabelled Del1 (amino acids 31-83) failed to compete with E5 and did not affect 
the E5-HC interaction (Figure 4D, lane 9).  
 
Taken together, these results conclusively show that E5 both physically interacts with HC and 
down-regulates surface HLA I via its first hydrophobic domain.  
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Discussion 
As is the case for the E5 oncoprotein of BPV 9-11, 16, the E5 oncoprotein of HPV-16 prevents 
the transport of HLA I to the cell surface and retains the complex in the Golgi apparatus 4. 
We have argued that the Golgi retention of MHC I by BPV-4 E5 is due to at least two events: 
the impaired acidification of the Golgi apparatus and the physical interaction of E5 with the 
heavy chain of MHC I.  
 
HPV-16 E5 interacts with HC. The interaction between E5 and the MHC I HC is not 
confined to BPV E5. HPV-16 E5 forms a stable complex with the HC of the HLA-A3 (and/or 
A31 B60 B51) of HaCaT keratinocytes, and in vitro also with the HC of HLA-A1, -A2 and -
B8. This interaction is therefore not specific for a particular HLA I haplotype/allele but it is 
likely to occur with most, if not all, HLA I. Complex formation between E5 and HC is 
responsible for down-regulation of surface HLA I, as a mutant of E5 which fails to bind HC, 
also fails to prevent the transport of HLA I to the cell surface, as discussed below.  
However, while the haplotype/allele of classical HLA I is not critical for E5-HC complex 
formation, E5 fails to down-regulate non-classical HLA I 4. These findings parallel those 
obtained with BPV-4 E5. BPV-4 E5 down-regulates classical MHC I independently of its 
type 16 and interacts with different HC (Marchetti et al., 2005), but fails to down-regulate non 
classical MHC I and to interact with the HC of a non-classical MHC I  (our unpublished 
results). It remains to be seen if HPV-16 E5 is capable of binding the HC of non-classical 
HLA I.    
 
The first N-terminus hydrophobic domain of E5 is essential for down-regulation of HLA I. 
HPV-16 E5 interacts also with 16k subunit c, a component of the vacuolar H+-ATPase 17. 
Previously published deletion mutants of E5 have been proficiently used to map the domain 
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of E5 mediating this interaction (see below; 8). These mutants and the new N-terminus 
deletion mutant of E5 showed the importance of the first N-terminus 30 amino acids in the 
interaction with, and down-regulation of, HLA I. The absence of the middle and last 
hydrophobic domains does not prevent down-regulation of surface HLA I, and the 30 amino 
acid-long N-terminus hydrophobic peptide is sufficient to prevent the traffic of HLA I to the 
cell surface. In contrast, the absence of the first hydrophobic N-terminus domain completely 
abolishes surface HLA I down-regulation. The impaired function of this Del1 mutant is not 
due to diminished expression or inappropriate cellular localisation, as both expression and 
localisation are comparable to those of E5 wt or the other mutants. Furthermore, Del1 fails to 
interact with the HLA I HC both in HaCaT cells and in vitro, the latter observation 
confirming that the inability of Del1 to complex with HC is not due to improper expression or 
location. Of importance is the fact that R30, comprising only the first 30 amino acids, is 
capable of interacting with and down-regulating HLA I to the same extent as E5 wt, thus 
largely eliminating the possibility that the failure of Del1 to down-regulate HLA I is due to 
improper configuration, instability or any other feature which may be peculiar to this deletion 
mutant.   
 
We have recently reported that BPV E5 interacts with the HC of bovine MHC I via its C-
terminus domain 10. This contrasts with the results presented here with HPV-16 E5 but this 
difference is not surprising. Despite their differences in length and presumed conformation, 
BPV E5 and HPV E5 share numerous functional similarities, one of them being the 
interference with the proper function of 16k ductin (and therefore of the vacuolar ATPase) 7. 
BPV E5 and HPV-16 E5 interact with 16k subunit c via different E5 domains: BPV E5 
interacts via its 17th amino acid residue (Q in BPV-1 E5, N in BPV-4 E5; 18, 19 whereas HPV-
16 E5 interacts via its second and third hydrophobic domains 8, 20. Thus, the same effects, 
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such as down-regulation of MHC I and disablement of the proton pump, can be achieved by 
distinct physical interactions with HC and subunit c, respectively. 
The interaction between HPV-16 E5 and 16k subunit c has been deemed responsible for the 
impaired functioning of the pump and the consequent lack of acidification of the 
endomembrane compartments 21, 22. Alkaline pH in the endolysosomes leads to delayed 
degradation and faster recycling of the epidermal growth factor receptor 22, 23, thus promoting 
increased cell proliferation. Studies with deletion mutants, including those employed by us 
here, have mapped the 16k-interacting domain of HPV-16 E5 to a relatively large region of 
E5 encompassing the second and third hydrophobic domains 8, 20. The observation that HPV-
16 E5 interacts with HC and 16k via different domains suggests that E5 can in principle bind 
the two cellular partners at the same time, thus simultaneously promoting immunomodulation 
and cell transformation, partly explaining the pleiotropic effects of E5 expression.   
 
We have commented before on the functional similarity between HPV-16 E5 and HIV-1 Nef. 
Both proteins prevent transport of classical HLA I to the cell surface in their natural host cells 
type 24, bind to the HLA I HC via the same domains needed for HLA I down-regulation 25 
and neither down-regulate non-classical HLA I 26; both bind 16k subunit c 27 and induce 
cytoskeletal rearrangements 28, 29, and induce epidermal hyperplasia when expressed in the 
basal layer of the skin of transgenic mice 30, 31. These similarities are intriguing and point to a 
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Figure 1. E5 and HLA I HC interact physically. A, co-immunoprecipitation of E5 and HLA I 
HC in HaCaT cells. Proteins from HaCaT cells harbouring empty vector (C), expressing Del1 
or E5, were either immunoblotted with mAb HC10 to detect HC, or first immunoprecipitated 
with mAb HA11 and immunoblotted with mAb HC10. Del1 is a deletion mutant of E5 which 
does not interact with HLA HC (see later). The double HC band, indicated by two black dots, 
more visible when co-immunoprecipitated with E5 (lane 7), may represent two or more of the 
HC alleles expressed by the cells. The heavy bands in the immunoprecipitations are Ig. 
Despite equal amounts of protein in the lanes, equal amounts/dilutions of antibody, and equal 
exposure time, the Ig bands have been consistently more pronounced in the 
immunoprecipitates from E5-expressing HaCaT cells. The reason for this effect is not known. 
Please note that the two Del1 IP lanes 5 and 6 represent two independent experiments. WB 
and IP of E5 and the second Del1 (lanes 2-5) were run in a separate but essentially identical 
gel and aligned for ease of comparison.  B, In vitro co-precipitation between E5 and HLA-A2 
HC. E5 and HC of HLA-A2 were transcribed/translated in vitro in the presence of 35S-
methionine and canine microsomes, mixed together and co-precipitated with mAb HC10 (anti 
HLA-A, -B, -C) (+ lanes). No precipitate was observed in the absence of the antibody (- lane 
6) or of A2 HC (lanes 4 and 5). A faint A2 band is visible in lane 2, despite the absence of 
antibody. C, E5 wt and E5 Del1 are expressed at comparable levels. Immunoblots of the 
same protein lysates in A, probed with mAb HA11. D-G, E5 interacts with HC from different 
HLA I haplotypes. E5 and HC of HLA-A1 and -B8 were transcribed/translated in vitro as in 
panel B and co-precipitated either with mAb HC10 (anti HLA-A, -B, -C; panels D and E) or 
mAb HA11 (anti the HA epitope of E5; panels F and G). A1, B8 and E5, were precipitated by 
their specific antibodies (+ lanes); A1 and E5, or B8 and E5 co-precipitated when incubated 
with either mAb HC10 (panels D and E; + lanes 7) or mAb HA11 (panels F and G; + lanes 
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7), and the co-immunoprecipitated bands were much stronger than in the absence of the 
antibody (- lanes). The E5 and HA bands are indicated by black dots; the other bands 
originate from the translated E5 protein (see input lanes) and may represent multimers of E5. 
  
Figure 2. Deletion mutants of E5 express to the same levels and have similar cellular 
localisation to E5 wt. A, Diagrammatic representation of E5 wt, showing the three 
hydrophobic domains, and E5 mutants, showing the missing domains of E5; B, Quantitative 
RT-PCR for E5 wt, E5 mutant and actin RNA, showing that the E5 mutants express at 
comparable levels; note that the right-hand Y axis represents the amount of E5 RNA and is 
1x10-4 that of the left-hand Y axis which represents the amount of actin RNA; C, Semi-
quantitative RT-PCR for E5 wt, E5 mutant and actin RNA, showing that E5 Del1 mutant 
express at levels comparable with E5 wt. The Y axis represents the band intensity after 25 
amplification cycles as measured by ImageQuant v5.2 software. D, GFP-fusion forms of E5 
wt or E5 mutants, transiently transfected in HaCaT keratinocytes, were visualised at the 
confocal microscope, along with the Golgi apparatus stained with BODIPY-TR-ceramide and 
the nucleus stained with DAPI. Only the merged images are presented (in greyscale) which 
show that E5 wt and mutants localise in the GA and ER. As the HaCaT cells were transiently 
transfected with the GFP plasmids, GFP-E5 fusion proteins are expressed only in a minority 
of cells. 
   
Figure 3. The first hydrophobic domain of E5 mediates the down-regulation of surface HLA 
I. A, HaCaT parental cells, HaCaT carrying empty vector, or expressing E5 wt or mutants 
were analysed by flow cytometry for surface (white bars) and total HLA I (grey bars). The 
average mean fluorescence was calculated from the flow cytometry analyses of two duplicate 
measurements from at least three clones of each cell line. The background (the reading of 
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cells stained with no primary antibody and only secondary antibody) was 0.4 in all cases. 
Standard deviation is shown. Del1 fails to down-regulate surface HLA I. The dotted line 
indicates the level of surface HLA I in parental and control cells. The HLA I values for Del1 
are boxed. 
B, The same cells were stained with mAb W6/32 and analysed by cytoimmunofluorescence. 
Del1 mutant failed to retain HLA I in the GA (highlighted with *). Although only a few cells 
are shown, the localisation of HLA I was the same in all cells of each clone. N, nucleus.  
 
Figure 4. Del1 does not bind HC. A, E5 wt, A54 and A2 HC were transcribed/translated in 
vitro in the presence of 35S-methionine and canine microsomes, mixed together and co-
precipitated with mAb HC10 (+ lanes). Co-precipitates were observed only in the presence of 
antibody and of A2 HC. B, R30, Del1 and A2 HC were processed as above. The only E5 
mutant that did not interact with A2 was Del1 (lane 6). C, R30 and HLA-A2 HC were 
transcribed/translated in vitro as above and precipitated with an antibody against the N-
terminus of E5 (10) (+ lanes). Co-precipitates were observed only in the presence of 
antibody. D, E5 wt and HLA-A2 HC were transcribed/translated and labelled in vitro as 
above; unlabelled R30 or Del1 were added to the reactions, and proteins precipitated with 
mAb HC10 (+ lanes). R30 competed with E5 wt and prevented its binding to HC (lane 4), 
while Del1 failed to do so (lane 9). Lanes 1 and 2 are the same as lanes 13 and 14, repeated 
for ease of comparison.  
In all panels, the co-precipitated E5, E5 mutants and HC bands are indicated by black dots; 
the other bands originate from the translated E5 protein (see input lanes) and may represent 
multimers of E5.   
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